<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:48:36Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9016550" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9016550</identifier>
        <datestamp>2022-04-20</datestamp>
        <setSpec>ict</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Integr Cancer Ther</journal-id>
              <journal-id journal-id-type="iso-abbrev">Integr Cancer Ther</journal-id>
              <journal-id journal-id-type="publisher-id">ICT</journal-id>
              <journal-id journal-id-type="hwp">spict</journal-id>
              <journal-title-group>
                <journal-title>Integrative Cancer Therapies</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1534-7354</issn>
              <issn pub-type="epub">1552-695X</issn>
              <publisher>
                <publisher-name>SAGE Publications</publisher-name>
                <publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9016550</article-id>
              <article-id pub-id-type="pmcid">PMC9016550</article-id>
              <article-id pub-id-type="pmc-uid">9016550</article-id>
              <article-id pub-id-type="pmid">35389288</article-id>
              <article-id pub-id-type="pmid">35389288</article-id>
              <article-id pub-id-type="doi">10.1177/15347354211063500</article-id>
              <article-id pub-id-type="publisher-id">10.1177_15347354211063500</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Quality of Life of Prostate Cancer Survivors Participating in a
Remotely Delivered Web-Based Behavioral Intervention Pilot Randomized
Trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5654-5542</contrib-id>
                  <name>
                    <surname>Langlais</surname>
                    <given-names>Crystal S.</given-names>
                  </name>
                  <degrees>MPH</degrees>
                  <xref rid="aff1-15347354211063500" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chen</surname>
                    <given-names>Yea-Hung</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff1-15347354211063500" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Van Blarigan</surname>
                    <given-names>Erin L.</given-names>
                  </name>
                  <degrees>ScD</degrees>
                  <xref rid="aff1-15347354211063500" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kenfield</surname>
                    <given-names>Stacey A.</given-names>
                  </name>
                  <degrees>ScD</degrees>
                  <xref rid="aff1-15347354211063500" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kessler</surname>
                    <given-names>Elizabeth R.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff2-15347354211063500" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Daniel</surname>
                    <given-names>Kimi</given-names>
                  </name>
                  <degrees>MS</degrees>
                  <xref rid="aff3-15347354211063500" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ramsdill</surname>
                    <given-names>Justin W.</given-names>
                  </name>
                  <degrees>MS</degrees>
                  <xref rid="aff3-15347354211063500" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Beer</surname>
                    <given-names>Tomasz M.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff3-15347354211063500" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Graff</surname>
                    <given-names>Rebecca E.</given-names>
                  </name>
                  <degrees>ScD</degrees>
                  <xref rid="aff1-15347354211063500" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Paich</surname>
                    <given-names>Kellie</given-names>
                  </name>
                  <degrees>MPH</degrees>
                  <xref rid="aff4-15347354211063500" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chan</surname>
                    <given-names>June M.</given-names>
                  </name>
                  <degrees>ScD</degrees>
                  <xref rid="aff1-15347354211063500" ref-type="aff">1</xref>
                  <xref rid="fn1-15347354211063500" ref-type="author-notes">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1706-8020</contrib-id>
                  <name>
                    <surname>Winters-Stone</surname>
                    <given-names>Kerri M.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff3-15347354211063500" ref-type="aff">3</xref>
                  <xref rid="fn1-15347354211063500" ref-type="author-notes">*</xref>
                  <xref rid="corresp1-15347354211063500" ref-type="corresp"/>
                </contrib>
              </contrib-group>
              <aff id="aff1-15347354211063500"><label>1</label>University of California, San
Francisco, CA, USA</aff>
              <aff id="aff2-15347354211063500"><label>2</label>University of Colorado School of
Medicine, University of Colorado Cancer Center, Aurora, CO, USA</aff>
              <aff id="aff3-15347354211063500"><label>3</label>Oregon Health &amp; Science University,
Portland, OR, USA</aff>
              <aff id="aff4-15347354211063500"><label>4</label>Movember Foundation, Culver City, CA,
USA</aff>
              <author-notes>
                <corresp id="corresp1-15347354211063500">Kerri M. Winters-Stone, Knight Cancer
Institute, Oregon Health Sciences University, 3455 SW US Veteran’s Hospital
Road, Mailcode KCRB-CPC, Portland, OR 97239, USA. Email:
<email>wintersk@ohsu.edu</email></corresp>
                <fn fn-type="other" id="fn1-15347354211063500">
                  <label>*</label>
                  <p>These authors contributed equally to this work.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="epub">
                <day>7</day>
                <month>4</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2022</year>
              </pub-date>
              <volume>21</volume>
              <elocation-id>15347354211063500</elocation-id>
              <history>
                <date date-type="received">
                  <day>15</day>
                  <month>6</month>
                  <year>2021</year>
                </date>
                <date date-type="rev-recd">
                  <day>9</day>
                  <month>11</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>12</day>
                  <month>11</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2022</copyright-statement>
                <copyright-year>2022</copyright-year>
                <copyright-holder content-type="sage">SAGE Publications</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p>
                </license>
              </permissions>
              <abstract>
                <sec id="section1-15347354211063500">
                  <title>Background:</title>
                  <p>Following a prostate cancer (PC) diagnosis, treatment-related symptoms may
result in diminished quality of life (QoL). Improved diet and increased
exercise may improve QoL in men with PC.</p>
                </sec>
                <sec id="section2-15347354211063500">
                  <title>Methods:</title>
                  <p>We conducted a 4-arm pilot randomized trial to assess feasibility and
acceptability of a 3-month web-based diet and exercise intervention, among
men (&gt;18 years of age) with PC (reported elsewhere). The purpose of this
study is to describe the change in QoL measured by surveys (eg, QLQ-C30,
PROMIS Fatigue) at enrollment and following the intervention. Men were
randomized 1:1:1:1 to increasing levels of web-based behavioral support:
Level 1: website; Level 2: Level 1 plus personalized diet and exercise
prescription; Level 3: Levels 1-2 plus Fitbit and text messages; Level 4:
Levels 1-3 plus 2 30-minute coaching calls. <italic toggle="yes">T</italic>-tests were
used to compare pre-post change in mean QoL scores between each Level and
Level 1.</p>
                </sec>
                <sec id="section3-15347354211063500">
                  <title>Results:</title>
                  <p>Two hundred and two men consented and were randomized (n = 49, 51, 50, 52 for
Levels 1-4, respectively). Men were predominantly white (93%), with a median
age of 70 years (Intra-quartile Range [IQR]: 65,75) and 3 years (IQR: 1,9)
post primary treatment for mostly localized disease (74% with T1-2). There
were no meaningful changes in QoL, but there were notable trends. Level 3
participants had small improvements in QLQ-C30 Global Health (5.46; 95% CI:
−0.02, 10.95) compared to Level 1. In contrast, Level 2 participants trended
toward decreasing Global QoL (−2.31, 95% CI: −8.05, 3.42), which may reflect
declines in function (eg, Cognitive: −6.94, 95% CI: −13.76, −0.13) and
higher symptom burden (eg, Diarrhea: 4.63, 95% CI: −1.48, 10.74).</p>
                </sec>
                <sec id="section4-15347354211063500">
                  <title>Conclusions:</title>
                  <p>This short, web-based intervention did not appear to have an impact on PC
survivors’ QoL. Most men were several years past treatment for localized
disease; the potential for this approach to reduce symptoms and improve QoL
in men who have worse health may still be warranted.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>cancer survivorship</kwd>
                <kwd>diet</kwd>
                <kwd>physical activity</kwd>
                <kwd>exercise</kwd>
                <kwd>patient-reported outcomes</kwd>
              </kwd-group>
              <funding-group specific-use="FundRef">
                <award-group id="award1-15347354211063500">
                  <funding-source id="funding1-15347354211063500">
                    <institution-wrap>
                      <institution>Movember Foundation</institution>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100008719</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="award2-15347354211063500">
                  <funding-source id="funding2-15347354211063500">
                    <institution-wrap>
                      <institution>National Cancer Institute</institution>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000054</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id rid="funding2-15347354211063500">F31CA247093</award-id>
                </award-group>
                <award-group id="award3-15347354211063500">
                  <funding-source id="funding3-15347354211063500">
                    <institution-wrap>
                      <institution>National Cancer Institute</institution>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000054</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id rid="funding3-15347354211063500">K07CA197077</award-id>
                </award-group>
                <award-group id="award4-15347354211063500">
                  <funding-source id="funding4-15347354211063500">
                    <institution-wrap>
                      <institution>National Institutes of Health</institution>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000002</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id rid="funding4-15347354211063500">P30CA069533-21</award-id>
                </award-group>
                <award-group id="award5-15347354211063500">
                  <funding-source id="funding5-15347354211063500">
                    <institution-wrap>
                      <institution>National Institutes of Health</institution>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000002</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id rid="funding5-15347354211063500">P30DK098722</award-id>
                </award-group>
                <award-group id="award6-15347354211063500">
                  <funding-source id="funding6-15347354211063500">
                    <institution-wrap>
                      <institution>National Center for Advancing Translational
Sciences</institution>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100006108</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id rid="funding6-15347354211063500">UL1TR001872</award-id>
                </award-group>
                <award-group id="award7-15347354211063500">
                  <funding-source id="funding7-15347354211063500">
                    <institution-wrap>
                      <institution>National Center for Advancing Translational
Sciences</institution>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100006108</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id rid="funding7-15347354211063500">UL1TR002369</award-id>
                </award-group>
                <award-group id="award8-15347354211063500">
                  <funding-source id="funding8-15347354211063500">
                    <institution-wrap>
                      <institution>Prostate Cancer Foundation</institution>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000892</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id rid="funding8-15347354211063500">Young Investigator Award</award-id>
                </award-group>
                <award-group id="award9-15347354211063500">
                  <funding-source id="funding9-15347354211063500">
                    <institution-wrap>
                      <institution>national institutes of health</institution>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000002</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id rid="funding9-15347354211063500">P30 CA069533</award-id>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>January-December 2022</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>typesetter</meta-name>
                  <meta-value>ts1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="section5-15347354211063500">
              <title>Background</title>
              <p>There are more than 3.1 million prostate cancer survivors in the United States.<sup><xref rid="bibr1-15347354211063500" ref-type="bibr">1</xref></sup> A prostate cancer diagnosis is most common in men aged 65 to 74 years and
roughly 98% of those diagnosed will survive 10 years or more.<sup><xref rid="bibr2-15347354211063500" ref-type="bibr">2</xref></sup> During this time, men may experience decreased quality of life (QoL) due to
the combined effects of the cancer diagnosis, concurrent co-morbidities, as well as
aging and side effects of prostate cancer treatment, including incontinence,
impotence, bowel dysfunction, fatigue, muscle loss, poor sleep quality, depression,
isolation and loneliness, and increased frailty.<sup><xref rid="bibr3-15347354211063500" ref-type="bibr">3</xref><xref rid="bibr4-15347354211063500" ref-type="bibr"/><xref rid="bibr5-15347354211063500" ref-type="bibr"/><xref rid="bibr6-15347354211063500" ref-type="bibr"/><xref rid="bibr7-15347354211063500" ref-type="bibr"/><xref rid="bibr8-15347354211063500" ref-type="bibr"/><xref rid="bibr9-15347354211063500" ref-type="bibr"/>-<xref rid="bibr10-15347354211063500" ref-type="bibr">10</xref></sup> Prior research suggests
treatment-related insults to QoL may subside in as little as 1 year after treatment,
particularly for men undergoing radical prostatectomy.<sup><xref rid="bibr11-15347354211063500" ref-type="bibr">11</xref>,<xref rid="bibr12-15347354211063500" ref-type="bibr">12</xref></sup> It is less clear how long
declines in physical, functional, emotional, and social well-being may last,
especially considering they may be compounded by age-related declines.</p>
              <p>An increasing body of evidence suggests that regular exercise, defined as 150 minutes
per week of aerobic exercise and ≥2 sessions per week of strength training activity,<sup><xref rid="bibr13-15347354211063500" ref-type="bibr">13</xref></sup> may improve prostate cancer clinical outcomes and QoL following diagnosis and
treatment.<sup><xref rid="bibr13-15347354211063500" ref-type="bibr">13</xref><xref rid="bibr14-15347354211063500" ref-type="bibr"/><xref rid="bibr15-15347354211063500" ref-type="bibr"/><xref rid="bibr16-15347354211063500" ref-type="bibr"/><xref rid="bibr17-15347354211063500" ref-type="bibr"/><xref rid="bibr18-15347354211063500" ref-type="bibr"/><xref rid="bibr19-15347354211063500" ref-type="bibr"/>-<xref rid="bibr20-15347354211063500" ref-type="bibr">20</xref></sup> However, few men met these
recommendations even when the evidence supporting them is strong. For example, in
addition to reducing the risk of prostate cancer progression<sup><xref rid="bibr17-15347354211063500" ref-type="bibr">17</xref>,<xref rid="bibr20-15347354211063500" ref-type="bibr">20</xref>,<xref rid="bibr21-15347354211063500" ref-type="bibr">21</xref></sup> and
mortality,<sup><xref rid="bibr17-15347354211063500" ref-type="bibr">17</xref>,<xref rid="bibr20-15347354211063500" ref-type="bibr">20</xref>,<xref rid="bibr22-15347354211063500" ref-type="bibr">22</xref><xref rid="bibr23-15347354211063500" ref-type="bibr"/><xref rid="bibr24-15347354211063500" ref-type="bibr"/><xref rid="bibr25-15347354211063500" ref-type="bibr"/>-<xref rid="bibr26-15347354211063500" ref-type="bibr">26</xref></sup> participating in regular
exercise, including aerobic and strength training activities, has been shown to
offset age-related declines and relieve treatment side-effects, thereby improving
prostate cancer survivors’ QoL.<sup><xref rid="bibr14-15347354211063500" ref-type="bibr">14</xref><xref rid="bibr15-15347354211063500" ref-type="bibr"/>-<xref rid="bibr16-15347354211063500" ref-type="bibr">16</xref></sup> Yet, &lt;25% of prostate
cancer survivors meet aerobic exercise recommendations and only 4% meet those for
resistance exercise.<sup><xref rid="bibr27-15347354211063500" ref-type="bibr">27</xref></sup></p>
              <p>Evidence also suggests that changing certain dietary habits may improve
disease-specific outcomes.<sup><xref rid="bibr20-15347354211063500" ref-type="bibr">20</xref>,<xref rid="bibr28-15347354211063500" ref-type="bibr">28</xref><xref rid="bibr29-15347354211063500" ref-type="bibr"/><xref rid="bibr30-15347354211063500" ref-type="bibr"/><xref rid="bibr31-15347354211063500" ref-type="bibr"/><xref rid="bibr32-15347354211063500" ref-type="bibr"/><xref rid="bibr33-15347354211063500" ref-type="bibr"/><xref rid="bibr34-15347354211063500" ref-type="bibr"/><xref rid="bibr35-15347354211063500" ref-type="bibr"/><xref rid="bibr36-15347354211063500" ref-type="bibr"/>-<xref rid="bibr37-15347354211063500" ref-type="bibr">37</xref></sup> Further, prior reports have
identified an association between healthy dietary patterns and higher levels or
health-related QoL in the general population,<sup><xref rid="bibr38-15347354211063500" ref-type="bibr">38</xref></sup> though less is known about the role of diet and QoL following a prostate
cancer diagnosis. However, age-associated changes themselves, including declining
muscle mass and changes in metabolism and physical functioning, can result in
dietary shifts and ultimately decreased enjoyment of or interest in dietary
intake.<sup><xref rid="bibr39-15347354211063500" ref-type="bibr">39</xref>,<xref rid="bibr40-15347354211063500" ref-type="bibr">40</xref></sup> In turn, poor nutrition among older adults has also been linked
to decreased appetite and diminished capability in performing activities of daily living.<sup><xref rid="bibr41-15347354211063500" ref-type="bibr">41</xref></sup></p>
              <p>Recognizing that a prostate cancer diagnosis may be a <italic toggle="yes">teachable
moment—</italic>affording an opportunity to improve adherence to behavioral
recommendations<sup><xref rid="bibr42-15347354211063500" ref-type="bibr">42</xref><xref rid="bibr43-15347354211063500" ref-type="bibr"/><xref rid="bibr44-15347354211063500" ref-type="bibr"/>-<xref rid="bibr45-15347354211063500" ref-type="bibr">45</xref></sup> —we conducted a pilot
randomized trial to assess the feasibility and acceptability of a web-based
intervention designed to support evidence-based dietary and exercise behaviors shown
to improve prostate cancer-specific outcomes,<sup><xref rid="bibr46-15347354211063500" ref-type="bibr">46</xref></sup> such as progression and disease-specific mortality.<sup><xref rid="bibr20-15347354211063500" ref-type="bibr">20</xref></sup> Prior analyses showed the intervention to be feasible with no serious adverse
effects and suggested it may modestly improve diet as well as exercise behaviors,
particularly among men who were not meeting physical activity recommendations at baseline.<sup><xref rid="bibr47-15347354211063500" ref-type="bibr">47</xref></sup> Additional data collected during the pilot study are relevant to
understanding the impact of such technology-based approaches on other outcomes
important to prostate cancer survivors. In this secondary analysis, we evaluate
whether this practical and scalable technology-based intervention can also improve
PC survivors’ QoL.</p>
            </sec>
            <sec sec-type="methods" id="section6-15347354211063500">
              <title>Methods</title>
              <sec id="section7-15347354211063500">
                <title>Study Population</title>
                <p>We conducted a multi-center 4-arm pilot randomized trial of a 3-month
intervention among men (&gt;18 years of age) with a self-reported diagnosis of
prostate cancer (clinicaltrials.gov NCT03406013). There were no restrictions on
stage of cancer or time since diagnosis. Men were identified through hospital
cancer registry databases and from the Cancer of the Prostate Strategic Urologic
Research Endeavor (CaPSURE) registry,<sup><xref rid="bibr48-15347354211063500" ref-type="bibr">48</xref></sup> and mailed a letter and study brochure directing men to contact research
staff to learn about the study. Study brochures were also placed in clinic
waiting and exam rooms. To participate, men were required to speak English, have
an email address, and have a personal device with internet and text messaging
capability. All participants provided written consent and all study-related
activities were done in accordance with and under the supervision of each study
site’s Institutional Review Board. Additional details have been reported elsewhere.<sup><xref rid="bibr46-15347354211063500" ref-type="bibr">46</xref></sup></p>
              </sec>
              <sec id="section8-15347354211063500">
                <title>Interventions</title>
                <p>Men were block randomized 1:1:1:1 to increasing levels of web-based behavioral
support. Participants randomized to <bold>Level 1</bold> received general
educational information regarding exercise and diet, including a resource
directory and study-specific guidelines posted on the study website.
Participants randomized to <bold>Level 2</bold> received Level 1 resources plus
personalized written diet and exercise recommendations, videos demonstrating
recommended exercises, and a weekly e-log to track progress toward meeting
recommendations. Participants randomized to <bold>Level 3</bold> received Level
1 to 2 resources plus text messages to support achieving diet and exercise
recommendations (average: 4 texts/week, no response required) and a Fitbit Alta
that integrated with the study website to display physical activity reports back
to the participant. Participants randomized to <bold>Level 4</bold> received
Level 1 to 3 resources plus access to two 30-minute coaching calls, 1 with an
exercise trainer and 1 with a registered dietician. Participants were told they
would be randomly assigned to receive access to websites with different tools
and resources but were unaware of the resources they received relative to other
participants. Additional details on randomization, interventions, and material
content have been reported previously.<sup><xref rid="bibr46-15347354211063500" ref-type="bibr">46</xref></sup></p>
              </sec>
              <sec id="section9-15347354211063500">
                <title>Quality of Life Assessments</title>
                <p>Patient-reported outcomes were assessed using both general population and
cancer-specific validated questionnaires. All QoL assessments were obtained at
study enrollment, at the end of intervention (3 months) and at 3-month follow-up
after intervention ended (6 months).</p>
                <sec id="section10-15347354211063500">
                  <title>QLQ-C30</title>
                  <p>The European Organization for the Research and Treatment of Cancer (EORTC)
Quality of Life Questionnaire-Core 30 (QLQ-C30) is a cancer-specific 30-item
questionnaire used to measure health-related QoL.<sup><xref rid="bibr49-15347354211063500" ref-type="bibr">49</xref></sup> The QLQ-C30 includes 5 functioning scales (physical, role, cognitive,
emotional, and social functioning), 3 symptom scales (fatigue, pain, nausea
and vomiting), 6 symptom items (dyspnea, insomnia, appetite loss,
constipation, diarrhea, financial difficulties), and a global health
status/QoL scale. Each scale’s score ranges from 0 to 100 points; a higher
score for global QoL and functioning reflect better health-related QoL or
functioning, while a higher symptom scale score reflects higher symptom
burden (eg, more severe pain). The QLQ-C30 scoring manual was used to
calculate the scores.<sup><xref rid="bibr50-15347354211063500" ref-type="bibr">50</xref></sup> Per scoring instructions, participants who responded to less than
half of the scale components did not have a score calculated for that scale
(ie, treated as missing; n = 57 for emotional functioning and financial
difficulties subscales, n = 56 for all others). We used guidelines published
in 2012 for interpreting longitudinal QoL score differences to quantify a
meaningful change (see Table 4 in Cocks et al<sup><xref rid="bibr51-15347354211063500" ref-type="bibr">51</xref></sup>), which expanded on the 1998 published guidelines.<sup><xref rid="bibr52-15347354211063500" ref-type="bibr">52</xref></sup></p>
                </sec>
                <sec id="section11-15347354211063500">
                  <title>PROMIS fatigue</title>
                  <p>In addition to the fatigue symptoms assessed by the QLQ-C30, we used the
Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue 8a
– Adult v1.0 questionnaire to assess participants’ fatigue.<sup><xref rid="bibr53-15347354211063500" ref-type="bibr">53</xref></sup> Consistent with the PROMIS scoring manual, responses to all questions
were summed and standardized using the T-Score Conversion Table.<sup><xref rid="bibr54-15347354211063500" ref-type="bibr">54</xref></sup> The standardized score ranges from 33.1 to 77.8 (corresponding to a
raw score of 8 to 40); a higher score is associated with greater symptoms of
fatigue. We used the cancer calibration cohort within the HealthMeasures<sup><xref rid="bibr55-15347354211063500" ref-type="bibr">55</xref></sup> Scoring Service (HM-SS) to impute responses for men who failed to
answer at least one, but not all, PROMIS Fatigue questions. Men who failed
to respond to at least 1 question were excluded from PROMIS analyses
(n = 57). We followed the general threshold of a 5-point change to represent
a minimally important difference, defined <italic toggle="yes">a priori.</italic></p>
                </sec>
                <sec id="section12-15347354211063500">
                  <title>PSQI</title>
                  <p>Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI)
validated questionnaire.<sup><xref rid="bibr56-15347354211063500" ref-type="bibr">56</xref>,<xref rid="bibr57-15347354211063500" ref-type="bibr">57</xref></sup> The PSQI
questionnaire evaluates 7 component scores (sleep quality, sleep latency,
sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep
medications, daytime dysfunction). Component scores range from 0 (no
difficulty) to 3 (severe difficulty) and are summed to generate a Global
PSQI Score ranging from 0 (no difficulty) to 21 (severe difficulty in all
areas). Men were considered non-responders and were excluded from the PSQI
analysis (n = 70) if they failed to respond to ≥1 of the questions. A global
score &lt;5 reflects good sleep quality.<sup><xref rid="bibr56-15347354211063500" ref-type="bibr">56</xref></sup></p>
                </sec>
              </sec>
              <sec id="section13-15347354211063500">
                <title>Statistical Analysis</title>
                <p>Assessing QoL was a stated secondary objective of our pilot randomized trial.<sup><xref rid="bibr46-15347354211063500" ref-type="bibr">46</xref></sup> Descriptive statistics of participants’ socio-demographics, clinical
characteristics, and randomization details are provided for each of the main QoL
scores. We compared change in patient-reported QoL measures between enrollment
and end of intervention for Levels 2, 3, and 4 compared to Level 1 via
<italic toggle="yes">t</italic>-tests. Where differences were observed, we planned to
report change in QoL measures between enrollment and 6 months to assess if
effects were maintained after the intervention ended. Results are reported as
mean change with 95% confidence intervals (CI). Paired <italic toggle="yes">t</italic>-tests
were also used to compare the 3-month QoL measures to the baseline QoL measures
within each level of intervention (see <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/15347354211063500" ext-link-type="uri">Supplemental Table 1</ext-link>).</p>
                <p>As secondary trial endpoints, all QoL analyses were conducted among men with
complete follow-up data. Though we report formal tests for change, our focus is
on patterns of change, rather than statistical significance, consistent with
guidelines for pilot trials.<sup><xref rid="bibr58-15347354211063500" ref-type="bibr">58</xref></sup> All analyses were conducted in R version 3.6.3 using two-sided hypothesis
testing and an alpha level of .05 to assess statistical significance.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="section14-15347354211063500">
              <title>Results</title>
              <p>A total of 202 men with prostate cancer were consented and randomized to increasing
levels of web-based behavioral support and provided access to the intervention: 49
assigned to Level 1, 51 to Level 2, 50 to Level 3, and 52 to Level 4. Of the 202 men
randomized, 161 (80%) accessed their intervention (38 in Level 1, 38 in Level 2, 42
in Level 3, and 42 in Level 4); 35 of the 202 men (17%) were lost to follow-up at
3 months and an additional 11 (5%) were lost to follow-up at 6 months. Attrition was
similar across levels. More details about study recruitment and retention were
reported previously.<sup><xref rid="bibr46-15347354211063500" ref-type="bibr">46</xref>,<xref rid="bibr47-15347354211063500" ref-type="bibr">47</xref></sup></p>
              <p>Men were predominantly white (93%) and well-educated (83% with 4-year college degree
or more). A total of 30 (15%) men reported receiving hormone therapy for the
treatment of their prostate cancer. The overall median (IQR) age at enrollment was
70 (65-75) and was similar across all levels. However, by chance, men in Level 1
were farther out from their prostate cancer diagnosis compared to the group as a
whole (median [IQR]: 9 years [4, 14] vs 4 years [2,10]). <xref rid="table1-15347354211063500" ref-type="table">Table 1</xref> shows median baseline QoL scores
by participant characteristics. Men diagnosed with higher T-stage (T3-T4) reported
lower median QLQ-C30 Global Health at baseline (75, IQR: 67, 83) compared to men
diagnosed with stage T1-T2 (83, IQR: 75, 92), though scores were similar across
other characteristics.</p>
              <table-wrap position="float" id="table1-15347354211063500">
                <label>Table 1.</label>
                <caption>
                  <p>Median Baseline QoL Scores by Sociodemographic and Clinical Characteristics
of 202 Prostate Cancer Survivors Participating in A Technology-Supported
Exercise and Dietary Intervention.</p>
                </caption>
                <alternatives>
                  <graphic xlink:href="10.1177_15347354211063500-table1" position="float"/>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                      <col align="char" char="." span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="center" rowspan="1" colspan="1">Characteristic</th>
                        <th align="center" rowspan="1" colspan="1">n (%)<sup><xref rid="table-fn2-15347354211063500" ref-type="table-fn">a</xref></sup></th>
                        <th align="center" rowspan="1" colspan="1">QLQ-C30 global health<sup><xref rid="table-fn3-15347354211063500" ref-type="table-fn">b</xref></sup></th>
                        <th align="center" rowspan="1" colspan="1">PROMIS fatigue<sup><xref rid="table-fn4-15347354211063500" ref-type="table-fn">c</xref></sup></th>
                        <th align="center" rowspan="1" colspan="1">PSQI<sup><xref rid="table-fn4-15347354211063500" ref-type="table-fn">c</xref></sup></th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">All participants</td>
                        <td rowspan="1" colspan="1">202 (100)</td>
                        <td rowspan="1" colspan="1">83.3 (75.0, 91.7)</td>
                        <td rowspan="1" colspan="1">46.4 (41.0, 49.2)</td>
                        <td rowspan="1" colspan="1">5.0 (3.0, 7.0)</td>
                      </tr>
                      <tr>
                        <td colspan="5" rowspan="1">Age</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> &lt;65</td>
                        <td rowspan="1" colspan="1">56 (27.7)</td>
                        <td rowspan="1" colspan="1">83.3 (75.0, 91.7)</td>
                        <td rowspan="1" colspan="1">46.7 (42.6, 51.2)</td>
                        <td rowspan="1" colspan="1">6.0 (4.0, 8.0)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> ≥65</td>
                        <td rowspan="1" colspan="1">146 (72.3)</td>
                        <td rowspan="1" colspan="1">83.3 (75.0, 91.7)</td>
                        <td rowspan="1" colspan="1">46.4 (41.0, 49.0)</td>
                        <td rowspan="1" colspan="1">5.0 (3.0, 7.0)</td>
                      </tr>
                      <tr>
                        <td colspan="5" rowspan="1">Race</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> White</td>
                        <td rowspan="1" colspan="1">187 (92.6)</td>
                        <td rowspan="1" colspan="1">83.3 (75.0, 91.7)</td>
                        <td rowspan="1" colspan="1">46.4 (41.0, 49.2)</td>
                        <td rowspan="1" colspan="1">5.0 (3.0, 7.0)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Other</td>
                        <td rowspan="1" colspan="1">13 (6.4)</td>
                        <td rowspan="1" colspan="1">83.3 (81.2, 85.4)</td>
                        <td rowspan="1" colspan="1">48.7 (44.0, 51.7)</td>
                        <td rowspan="1" colspan="1">8.0 (6.0, 8.5)</td>
                      </tr>
                      <tr>
                        <td colspan="5" rowspan="1">Education</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> ≤ High school</td>
                        <td rowspan="1" colspan="1">15 (7.4)</td>
                        <td rowspan="1" colspan="1">83.3 (83.3, 100.0)</td>
                        <td rowspan="1" colspan="1">47.7 (41.3, 48.7)</td>
                        <td rowspan="1" colspan="1">5.5 (4.0, 7.0)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> 2- or 4- year college</td>
                        <td rowspan="1" colspan="1">78 (38.6)</td>
                        <td rowspan="1" colspan="1">83.3 (75.0, 91.7)</td>
                        <td rowspan="1" colspan="1">46.4 (41.0, 51.2)</td>
                        <td rowspan="1" colspan="1">5.0 (3.0, 7.0)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Grad/prof degree</td>
                        <td rowspan="1" colspan="1">109 (54.0)</td>
                        <td rowspan="1" colspan="1">83.3 (75.0, 91.7)</td>
                        <td rowspan="1" colspan="1">46.4 (41.0, 48.7)</td>
                        <td rowspan="1" colspan="1">5.0 (3.0, 8.0)</td>
                      </tr>
                      <tr>
                        <td colspan="5" rowspan="1">PSA<sup><xref rid="table-fn5-15347354211063500" ref-type="table-fn">d</xref></sup></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> ≤10 ng/mL</td>
                        <td rowspan="1" colspan="1">129 (63.9)</td>
                        <td rowspan="1" colspan="1">83.3 (75.0, 91.7)</td>
                        <td rowspan="1" colspan="1">46.6 (41.2, 49.2)</td>
                        <td rowspan="1" colspan="1">5.0 (3.0, 8.0)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> &gt;10 ng/mL</td>
                        <td rowspan="1" colspan="1">48 (23.8)</td>
                        <td rowspan="1" colspan="1">83.3 (75.0, 91.7)</td>
                        <td rowspan="1" colspan="1">46.4 (40.9, 48.8)</td>
                        <td rowspan="1" colspan="1">5.0 (3.2, 7.0)</td>
                      </tr>
                      <tr>
                        <td colspan="5" rowspan="1">T-stage</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> T1-T2</td>
                        <td rowspan="1" colspan="1">149 (73.8)</td>
                        <td rowspan="1" colspan="1">83.3 (75.0, 91.7)</td>
                        <td rowspan="1" colspan="1">45.4 (35.2, 48.7)</td>
                        <td rowspan="1" colspan="1">5.0 (3.0, 7.0)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> T3-T4</td>
                        <td rowspan="1" colspan="1">40 (19.8)</td>
                        <td rowspan="1" colspan="1">75.0 (66.7, 83.3)</td>
                        <td rowspan="1" colspan="1">48.7 (46.7, 53.0)</td>
                        <td rowspan="1" colspan="1">6.0 (4.5, 8.5)</td>
                      </tr>
                      <tr>
                        <td colspan="5" rowspan="1">Gleason</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> &lt;7</td>
                        <td rowspan="1" colspan="1">38 (18.8)</td>
                        <td rowspan="1" colspan="1">83.3 (83.3, 97.9)</td>
                        <td rowspan="1" colspan="1">46.4 (41.3, 49.1)</td>
                        <td rowspan="1" colspan="1">6.0 (2.0, 7.0)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> 7</td>
                        <td rowspan="1" colspan="1">80 (39.6)</td>
                        <td rowspan="1" colspan="1">83.3 (66.7, 91.7)</td>
                        <td rowspan="1" colspan="1">46.4 (41.0, 48.7)</td>
                        <td rowspan="1" colspan="1">5.0 (3.0, 7.2)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> &gt;7</td>
                        <td rowspan="1" colspan="1">46 (22.8)</td>
                        <td rowspan="1" colspan="1">83.3 (66.7, 83.3)</td>
                        <td rowspan="1" colspan="1">46.7 (44.1, 50.1)</td>
                        <td rowspan="1" colspan="1">5.0 (4.0, 8.5)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ADT<sup><xref rid="table-fn6-15347354211063500" ref-type="table-fn">e</xref></sup></td>
                        <td rowspan="1" colspan="1">30 (14.9)</td>
                        <td rowspan="1" colspan="1">83.3 (75.0, 100)</td>
                        <td rowspan="1" colspan="1">44.1 (35.1, 49.5)</td>
                        <td rowspan="1" colspan="1">4.0 (3.0, 5.8)</td>
                      </tr>
                      <tr>
                        <td colspan="5" rowspan="1">Levels</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Level 1</td>
                        <td rowspan="1" colspan="1">49 (24.3)</td>
                        <td rowspan="1" colspan="1">83.3 (75.0, 95.8)</td>
                        <td rowspan="1" colspan="1">46.4 (44.0, 49.1)</td>
                        <td rowspan="1" colspan="1">5.0 (3.0, 7.0)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Level 2</td>
                        <td rowspan="1" colspan="1">51 (25.2)</td>
                        <td rowspan="1" colspan="1">83.3 (75.0, 91.7)</td>
                        <td rowspan="1" colspan="1">47.7 (41.4, 51.2)</td>
                        <td rowspan="1" colspan="1">5.0 (3.8, 8.0)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Level 3</td>
                        <td rowspan="1" colspan="1">50 (24.8)</td>
                        <td rowspan="1" colspan="1">83.3 (75.0, 91.7)</td>
                        <td rowspan="1" colspan="1">44.2 (36.5, 48.7)</td>
                        <td rowspan="1" colspan="1">5.0 (2.0, 7.0)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Level 4</td>
                        <td rowspan="1" colspan="1">52 (25.7)</td>
                        <td rowspan="1" colspan="1">83.3 (66.7, 91.7)</td>
                        <td rowspan="1" colspan="1">46.7 (38.2, 49.8)</td>
                        <td rowspan="1" colspan="1">5.0 (4.0, 7.0)</td>
                      </tr>
                    </tbody>
                  </table>
                </alternatives>
                <table-wrap-foot>
                  <fn id="table-fn1-15347354211063500">
                    <p>Abbreviations: ADT, androgen deprivation therapy; PROMIS, patient
reported outcomes measurement system; PSA, prostate-specific antigen;
PSQI, Pittsburgh sleep quality index; QLQ-C30, Quality of Life
Questionnaire-Core 30; QoL, quality of life.</p>
                  </fn>
                  <fn id="table-fn2-15347354211063500">
                    <label>a</label>
                    <p>Percentages may not sum 100% due to missingness: 2 men with unknown race,
25 men with unknown diagnostic PSA, 13 with unknown T-stage, 38 with
unknown Gleason.</p>
                  </fn>
                  <fn id="table-fn3-15347354211063500">
                    <label>b</label>
                    <p>Higher score reflects better QoL.</p>
                  </fn>
                  <fn id="table-fn4-15347354211063500">
                    <label>c</label>
                    <p>Lower score reflects less fatigue/symptom burden.</p>
                  </fn>
                  <fn id="table-fn5-15347354211063500">
                    <label>d</label>
                    <p>Median PSA value at diagnosis was 6.4 ng/mL.</p>
                  </fn>
                  <fn id="table-fn6-15347354211063500">
                    <label>e</label>
                    <p>Reflects the number of men on active ADT treatment at enrollment. Two men
reported active chemotherapy and 1 man reported active radiation
therapy; counts were too low to summarize across scores.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <sec id="section15-15347354211063500">
                <title>QLQ-C30</title>
                <p>Mean changes in the QLQ-C30 are shown in <xref rid="fig1-15347354211063500" ref-type="fig">Figure 1</xref>. Generally, most confidence
intervals crossed 0 (ie, included the null), but there were notable trends.
Compared to Level 1, men assigned to Level 2 tended to report worsening role,
emotional, and cognitive functioning at 3 months, and increasing burden of
fatigue, insomnia, diarrhea, and financial difficulties (<xref rid="fig1-15347354211063500" ref-type="fig">Figure 1</xref>), resulting in a decreasing
Global Health measure at 3 months (−2.31, 95% CI: −8.05, 3.42). Level 4
participants also reported a trend toward decreasing Global Health status
compared to Level 1 (−1.52, 95% CI: −6.78, 3.74), though the only notable
decline reported was an increase in financial difficulties. Conversely, there
was a trend toward improving Global Health Status for men in Level 3 versus 1
(5.46, 95% CI: −0.02, 10.95), reflecting a small, but meaningful change.<sup><xref rid="bibr51-15347354211063500" ref-type="bibr">51</xref></sup> Correspondingly, Level 3 reported improving emotional function and
symptoms, including declining appetite loss, constipation, and diarrhea. The
within-level mean change from baseline to 3-months is provided in <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/15347354211063500" ext-link-type="uri">Supplemental Table 1</ext-link>.</p>
                <fig position="float" id="fig1-15347354211063500">
                  <label>Figure 1.</label>
                  <caption>
                    <p>Mean change in QLQ-C30 sub-scales compared to level 1. (A) QLQ-C30 global
health and function scales (a positive change score reflects better
health/functioning comparing the level to the referent level). (B)
QLQ-C30 symptoms scales and items (a negative change score reflects
lower symptom burden comparing the level to the referent level).</p>
                  </caption>
                  <graphic xlink:href="10.1177_15347354211063500-fig1" position="float"/>
                </fig>
              </sec>
              <sec id="section16-15347354211063500">
                <title>PROMIS Fatigue Score</title>
                <p>Mean changes in PROMIS Fatigue scores are shown in <xref rid="fig2-15347354211063500" ref-type="fig">Figure 2</xref>. Level 2 participants had
increasing fatigue symptoms compared to Level 1 (3.24, 95% CI: 0.77, 5.71), with
an upward trend also observed among Level 4 versus Level 1 participants (2.11,
95% CI: −0.82, 5.04). However, neither point estimate reached our <italic toggle="yes">a
priori</italic> threshold of meaningful change (5 points). Level 3
participants did not demonstrate differences from men in Level 1 (0.39, 95% CI:
−2.32, 3.11). The within-level mean change from baseline to 3-months is provided
in <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/15347354211063500" ext-link-type="uri">Supplemental Table 1</ext-link>.</p>
                <fig position="float" id="fig2-15347354211063500">
                  <label>Figure 2.</label>
                  <caption>
                    <p>Mean change in PROMIS fatigue<sup>a</sup> and PSQI sleep
index<sup>b</sup> scores compared to level 1.</p>
                    <p><sup>a</sup>A positive change score is associated with greater fatigue
comparing the level to the referent level.</p>
                    <p><sup>b</sup>A positive change score is associated with worse sleep
quality comparing the level to the referent level.</p>
                  </caption>
                  <graphic xlink:href="10.1177_15347354211063500-fig2" position="float"/>
                </fig>
              </sec>
              <sec id="section17-15347354211063500">
                <title>PSQI</title>
                <p>Mean changes in PSQI scores are shown in <xref rid="fig2-15347354211063500" ref-type="fig">Figure 2</xref>. There was essentially no
change for men in Level 4 (0.14, 95% CI: −1.01, 1.29), Level 3 (0.31, 95% CI:
−0.87, 1.49) or Level 2 (0.70, 95% CI: −0.47, 1.88) compared to Level 1
participants. The within-level mean change from baseline to 3-months is provided
in <ext-link xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/15347354211063500" ext-link-type="uri">Supplemental Table 1</ext-link>.</p>
                <p>Given the lack of substantial change observed between baseline and 3 months, we
did not analyze 6-month follow-up data.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="section18-15347354211063500">
              <title>Discussion</title>
              <p>The primary aim of this pilot randomized trial was to assess the feasibility and
acceptability of the web-based diet and exercise intervention. Findings from that
analysis showed that the intervention was feasible and men were satisfied with the
intervention, particularly those randomized to level 4. We also reported small
improvements in diet and physical activity at 3 months for men randomized to level 4
versus level 1. Physical activity improvements were strongest among men who were
insufficiently active at enrollment.<sup><xref rid="bibr47-15347354211063500" ref-type="bibr">47</xref></sup> In this analysis of secondary outcomes, we observed little change in
cancer-specific QoL outcomes among prostate cancer survivors participating in a
pilot, 3-month, web-based intervention offering varying levels of educational
information and behavioral support to improve diet and exercise behaviors. There may
be several reasons for these results. First, it is possible that the intervention,
though modestly effective at improving diet and exercise habits associated with
improved prostate cancer outcomes,<sup><xref rid="bibr47-15347354211063500" ref-type="bibr">47</xref></sup> may not improve QoL. Second, study participants were mostly diagnosed with
localized prostate cancer. Prior studies have reported that QoL is notably better in
men diagnosed with localized versus advanced disease.<sup><xref rid="bibr59-15347354211063500" ref-type="bibr">59</xref></sup> Indeed, our lowest global QoL scores were observed among the 40 men diagnosed
with T3-T4 disease and our baseline scores suggest that, overall, men had relatively
high global QoL and functioning scores and low symptom burden. These high initial
values could create a ceiling effect that may explain the limited influence of the
intervention. A related reason may be that men in this study were a median of
3 years (IQR: 1, 9) out from their primary treatment for prostate cancer. There are
both short- and long-term side effects associated with primary therapy, and these
may differ in timing of effect, depending on type of therapy received.<sup><xref rid="bibr6-15347354211063500" ref-type="bibr">6</xref><xref rid="bibr7-15347354211063500" ref-type="bibr"/><xref rid="bibr8-15347354211063500" ref-type="bibr"/>-<xref rid="bibr9-15347354211063500" ref-type="bibr">9</xref>,<xref rid="bibr60-15347354211063500" ref-type="bibr">60</xref>,<xref rid="bibr61-15347354211063500" ref-type="bibr">61</xref></sup> Given this variability, it is
also possible that clear patterns of change could not be observed, given our limited
sample size and inability to examine participants based on these factors.</p>
              <p>Some trends were observed within the 3 QoL metrics examined. Compared to Level 1,
Level 2 participants demonstrated some decreases in QoL over the course of the
intervention. There was also some evidence of a meaningful increase in QoL for Level
3 and a (nonmeaningful) decrease in QoL for Level 4 participants, though these
trends were not consistent across all metrics. Given this lack of consistency and
the possibility of chance findings due to multiple comparison, we caution against
drawing conclusions from these noted trends. It is necessary to determine
population-specific thresholds for meaningful clinical change. The EORTC<sup><xref rid="bibr62-15347354211063500" ref-type="bibr">62</xref></sup> Quality of Life Group (QLG) supported the minimally important difference
(MID) project whose aim was to establish MIDs for QLQ-C30 questionnaires according
to cancer site.Notably, MID guidelines for prostate cancer have not yet been
published, nor have MIDs been published for other scores within similar populations
of prostate cancer survivors. Thus, general guidelines for meaningful change were
used, as noted in the methods. However, previous literature suggest that these
thresholds may vary by population and cancer type, in addition to QLQ-C30 sub-scale,
and even the direction of change (ie, whether a positive score reflects better or
worse QoL).<sup><xref rid="bibr51-15347354211063500" ref-type="bibr">51</xref>,<xref rid="bibr63-15347354211063500" ref-type="bibr">63</xref><xref rid="bibr64-15347354211063500" ref-type="bibr"/>-<xref rid="bibr65-15347354211063500" ref-type="bibr">65</xref></sup> QLG MID project investigators
have announced future plans to develop MIDs specific to prostate cancer, which may
provide an opportunity to re-evaluate findings from this study. As a related
example, although the change in PROMIS fatigue score did not reach the <italic toggle="yes">a
priori</italic> threshold of meaningful change, Yost et al<sup><xref rid="bibr66-15347354211063500" ref-type="bibr">66</xref></sup> noted a change score of 3 to 5 points using the 7-item PROMIS fatigue
questionnaire in men with prostate cancer was a MID. A similar analysis to clarify
MID for the 8-item PROMIS fatigue questionnaire used in this study may better inform
these findings.</p>
              <p>There are several limitations of this study to consider. The intervention was of
limited duration and we did not select men with low baseline QoL scores. Men were
diagnosed with different stages of disease, varied in their time since diagnosis,
and were at varying points in their treatment pathway, all of which may influence
QoL. We also acknowledge that men who self-select to participate in a lifestyle
study may have better QoL than men who opt out. Further, the intervention was not
specifically designed to improve QoL, nor powered to detect differences for this
secondary outcome; any statistically significant results should be evaluated
cautiously. Attrition may be more common among men experiencing increased symptom
burden and decreased QoL. To the extent this is true, we may have missed a decline
in QoL due to attrition, though rate of attrition was balanced across Levels.
Lastly, individuals who volunteered were predominately white and highly educated
which limits generalizability. Despite these potential shortcomings, given limited
data on the impact of web-enhanced interventions to improve QoL in PC survivors,
this report may be informative for future studies. Such studies may wish to consider
a longer intervention period, inclusion of additional tools targeted at modifying
specific QoL metrics (eg, meditation to reduce anxiety), and focus on men with worse
disease severity or a greater burden of treatment.</p>
            </sec>
            <sec sec-type="conclusions" id="section19-15347354211063500">
              <title>Conclusion</title>
              <p>This 3-month web-based intervention did not appear to have a meaningful impact on
prostate cancer survivors’ health-related QoL, sleep quality, or fatigue levels in
the pilot sample. However, given the relative healthiness of the study population at
enrollment, conclusions about the potential of this approach to reduce symptoms and
improve QoL in men with more advanced disease or those more proximal to their
primary treatment may still be warranted. Additionally, Black/African-American men
bear a greater burden of prostate cancer morbidity and mortality and are often
under-represented in lifestyle intervention trials.<sup><xref rid="bibr20-15347354211063500" ref-type="bibr">20</xref>,<xref rid="bibr67-15347354211063500" ref-type="bibr">67</xref>,<xref rid="bibr68-15347354211063500" ref-type="bibr">68</xref></sup> To address this, our team is
conducting a qualitative assessment of preferences regarding diet and exercise
resources for behavioral change, among non-white men with prostate cancer, to inform
future tailored interventions. Overall, this pilot study suggests that in a
population of more educated, white men with early-stage prostate cancer, more
comprehensive (and/or longer) interventions may be needed to modify behavior to
improve meaningfully QoL, sleep, and fatigue.</p>
            </sec>
            <sec sec-type="supplementary-material" id="section20-15347354211063500" specific-use="figshare">
              <title>Supplemental Material</title>
              <supplementary-material id="suppl1-15347354211063500" position="float" content-type="local-data">
                <caption>
                  <title>sj-docx-1-ict-10.1177_15347354211063500 – Supplemental material for
Quality of Life of Prostate Cancer Survivors Participating in a Remotely
Delivered Web-Based Behavioral Intervention Pilot Randomized Trial</title>
                </caption>
                <media xlink:href="sj-docx-1-ict-10.1177_15347354211063500.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
                <p>Supplemental material, sj-docx-1-ict-10.1177_15347354211063500 for Quality of
Life of Prostate Cancer Survivors Participating in a Remotely Delivered
Web-Based Behavioral Intervention Pilot Randomized Trial by Crystal S. Langlais,
Yea-Hung Chen, Erin L. Van Blarigan, Stacey A. Kenfield, Elizabeth R. Kessler,
Kimi Daniel, Justin W. Ramsdill, Tomasz M. Beer, Rebecca E. Graff, Kellie Paich,
June M. Chan and Kerri M. Winters-Stone in Integrative Cancer Therapies</p>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <p>We would like to thank the participants of the trial who made this research
possible.</p>
            </ack>
            <fn-group>
              <fn fn-type="other">
                <p><bold>Authors’ Note:</bold> Its contents are solely the responsibility of the authors and do not necessarily
represent the official views of the NIH.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p><bold>Declaration of Conflicting Interests:</bold> The author(s) declared the following potential conflicts of interest with respect
to the research, authorship, and/or publication of this article: SAK is
associated with Fellow Health Inc. TMB is associated with AbbVie, Alliance
Foundation Trials, Arvinas Inc, Astellas, AstraZeneca, Bayer, Boehringer
Ingelheim, Clovis Oncology, Corcept Therapeutics, Endocyte Inc, GlaxoSmithKline,
Janssen Biotech, Janssen Japan, Janssen Research &amp; Development, Medivation,
Inc, Merck, OncoGenex, Pfizer, Salarius Pharmaceuticals, Sotio, Theraclone
Sciences/OncoResponse. JMC’s spouse is employed by GRAIL Inc. KP is employed by
Movember. The authors are the developers/sponsors of the intervention evaluated
in this report.</p>
              </fn>
              <fn fn-type="financial-disclosure">
                <p><bold>Funding:</bold> The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: This work was
supported by the Movember Foundation; Prostate Cancer Foundation Young
Investigator Award; the National Center for Advancing Translational Sciences
[Grant Numbers UL1 TR001872 and UL1TR002369]; and other NIH grants [P30DK098722,
P30CA069533-21, P30CA069533, NCI K07CA197077, and NCI F31CA247093].</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Ethics Approval and Consent to Participate:</bold> All participants provided written consent, and all study-related activities were
performed in accordance with and under the supervision of the institutional
review board of each study site.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>ORCID iDs:</bold> Crystal S. Langlais <inline-graphic xlink:href="10.1177_15347354211063500-img1.jpg"/>
<ext-link xlink:href="https://orcid.org/0000-0001-5654-5542" ext-link-type="uri">https://orcid.org/0000-0001-5654-5542</ext-link></p>
                <p>Kerri M. Winters-Stone <inline-graphic xlink:href="10.1177_15347354211063500-img1.jpg"/>
<ext-link xlink:href="https://orcid.org/0000-0003-1706-8020" ext-link-type="uri">https://orcid.org/0000-0003-1706-8020</ext-link></p>
              </fn>
              <fn fn-type="supplementary-material">
                <p><bold>Supplemental Material:</bold> Supplemental material for this article is available online.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Availability of Data and Materials:</bold> The datasets used during the current study may be available from the
corresponding author on reasonable request.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="bibr1-15347354211063500">
                <label>1</label>
                <mixed-citation publication-type="webpage"><collab>American Cancer Society</collab>. <article-title>Cancer facts and
figures 2020</article-title>. <year>2020</year>. <comment>Accessed November
9, 2020</comment>. <ext-link xlink:href="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf" ext-link-type="uri">https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf</ext-link>.</mixed-citation>
              </ref>
              <ref id="bibr2-15347354211063500">
                <label>2</label>
                <mixed-citation publication-type="book"><collab>SEER*Explorer</collab>. <article-title>An interactive website for SEER
cancer statistics</article-title>. <publisher-name>Surveillance Research
Program, National Cancer Institute</publisher-name>. 2020. <comment>Accessed
November 9, 2020</comment>. <ext-link xlink:href="https://seer.cancer.gov/explorer/" ext-link-type="uri">https://seer.cancer.gov/explorer/</ext-link></mixed-citation>
              </ref>
              <ref id="bibr3-15347354211063500">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winters-Stone</surname><given-names>KM</given-names></name><name><surname>Moe</surname><given-names>E</given-names></name><name><surname>Graff</surname><given-names>JN</given-names></name></person-group>, <etal>et al</etal>. <article-title>Falls and frailty in
prostate cancer survivors: current, past, and never users of Androgen
deprivation therapy</article-title>. <source>J Am Geriatr Soc</source>.
<year>2017</year>;<volume>65</volume>:<fpage>1414</fpage>-<lpage>1419</lpage>.<pub-id pub-id-type="pmid">28263373</pub-id></mixed-citation>
              </ref>
              <ref id="bibr4-15347354211063500">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iadeluca</surname><given-names>L</given-names></name><name><surname>Mardekian</surname><given-names>J</given-names></name><name><surname>Chander</surname><given-names>P</given-names></name><name><surname>Hopps</surname><given-names>M</given-names></name><name><surname>Makinson</surname><given-names>GT.</given-names></name></person-group><article-title>The burden of selected cancers in the US: health behaviors and
health care resource utilization</article-title>. <source>Cancer Manag
Res</source>.
<year>2017</year>;<volume>9</volume>:<fpage>721</fpage>-<lpage>730</lpage>.<pub-id pub-id-type="pmid">29238222</pub-id></mixed-citation>
              </ref>
              <ref id="bibr5-15347354211063500">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leach</surname><given-names>CR</given-names></name><name><surname>Bellizzi</surname><given-names>KM</given-names></name><name><surname>Hurria</surname><given-names>A</given-names></name><name><surname>Reeve</surname><given-names>BB.</given-names></name></person-group><article-title>Is it my cancer or am i just getting older? Impact of cancer on
age-related health conditions of older cancer survivors</article-title>.
<source>Cancer</source>.
<year>2016</year>;<volume>122</volume>:<fpage>1946</fpage>-<lpage>1953</lpage>.<pub-id pub-id-type="pmid">27159822</pub-id></mixed-citation>
              </ref>
              <ref id="bibr6-15347354211063500">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>D</given-names></name><name><surname>Joseph</surname><given-names>DJ</given-names></name><name><surname>Ebert</surname><given-names>MA</given-names></name></person-group>, <etal>et al</etal>. <article-title>Effect of androgen
deprivation therapy on muscle attenuation in men with prostate
cancer</article-title>. <source>J Med Imaging Radiat Oncol</source>.
<year>2014</year>;<volume>58</volume>:<fpage>223</fpage>-<lpage>228</lpage>.<pub-id pub-id-type="pmid">24118850</pub-id></mixed-citation>
              </ref>
              <ref id="bibr7-15347354211063500">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galvão</surname><given-names>DA</given-names></name><name><surname>Taaffe</surname><given-names>DR</given-names></name><name><surname>Spry</surname><given-names>N</given-names></name><name><surname>Joseph</surname><given-names>D</given-names></name><name><surname>Turner</surname><given-names>D</given-names></name><name><surname>Newton</surname><given-names>RU.</given-names></name></person-group><article-title>Reduced muscle strength and functional performance in men with
prostate cancer undergoing androgen suppression: a comprehensive
cross-sectional investigation</article-title>. <source>Prostate Cancer
Prostatic Dis</source>.
<year>2009</year>;<volume>12</volume>:<fpage>198</fpage>-<lpage>203</lpage>.<pub-id pub-id-type="pmid">18852703</pub-id></mixed-citation>
              </ref>
              <ref id="bibr8-15347354211063500">
                <label>8</label>
                <mixed-citation publication-type="book"><collab>Prostate Cancer Foudation</collab>. <article-title>Prostate cancer side
effects</article-title>. <publisher-name>Prostate Cancer
Foundation</publisher-name>. 2020. <comment>Accessed March 9,
2020</comment>. <ext-link xlink:href="https://www.pcf.org/about-prostate-cancer/prostate-cancer-side-effects/" ext-link-type="uri">https://www.pcf.org/about-prostate-cancer/prostate-cancer-side-effects/</ext-link></mixed-citation>
              </ref>
              <ref id="bibr9-15347354211063500">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koskderelioglu</surname><given-names>A</given-names></name><name><surname>Gedizlioglu</surname><given-names>M</given-names></name><name><surname>Ceylan</surname><given-names>Y</given-names></name><name><surname>Gunlusoy</surname><given-names>B</given-names></name><name><surname>Kahyaoglu</surname><given-names>N.</given-names></name></person-group><article-title>Quality of sleep in patients receiving androgen deprivation
therapy for prostate cancer</article-title>. <source>Neurol Sci</source>.
<year>2017</year>;<volume>38</volume>:<fpage>1445</fpage>-<lpage>1451</lpage>.<pub-id pub-id-type="pmid">28484881</pub-id></mixed-citation>
              </ref>
              <ref id="bibr10-15347354211063500">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eton</surname><given-names>DT</given-names></name><name><surname>Lepore</surname><given-names>SJ.</given-names></name></person-group><article-title>Prostate cancer and health-related quality of life: a review of
the literature</article-title>. <source>Psychooncology</source>.
<year>2002</year>;<volume>11</volume>:<fpage>307</fpage>-<lpage>326</lpage>.<pub-id pub-id-type="pmid">12203744</pub-id></mixed-citation>
              </ref>
              <ref id="bibr11-15347354211063500">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lubeck</surname><given-names>DP</given-names></name><name><surname>Litwin</surname><given-names>MS</given-names></name><name><surname>Henning</surname><given-names>JM</given-names></name><name><surname>Stoddard</surname><given-names>ML</given-names></name><name><surname>Flanders</surname><given-names>SC</given-names></name><name><surname>Carroll</surname><given-names>PR.</given-names></name></person-group><article-title>Changes in health-related quality of life in the first year after
treatment for prostate cancer: results from CaPSURE</article-title>.
<source>Urology</source>.
<year>1999</year>;<volume>53</volume>:<fpage>180</fpage>-<lpage>186</lpage>.<pub-id pub-id-type="pmid">9886609</pub-id></mixed-citation>
              </ref>
              <ref id="bibr12-15347354211063500">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Litwin</surname><given-names>MS</given-names></name><name><surname>McGuigan</surname><given-names>KA</given-names></name><name><surname>Shpall</surname><given-names>AI</given-names></name><name><surname>Dhanani</surname><given-names>N.</given-names></name></person-group><article-title>Recovery of health related quality of life in the year after
radical prostatectomy: early experience</article-title>. <source>J
Urol</source>.
<year>1999</year>;<volume>161</volume>:<fpage>515</fpage>-<lpage>519</lpage>.<pub-id pub-id-type="pmid">9915438</pub-id></mixed-citation>
              </ref>
              <ref id="bibr13-15347354211063500">
                <label>13</label>
                <mixed-citation publication-type="book"><collab>Department of Health and Human Services</collab>. <source>Physical
Activity Guidelines for Americans</source>. <edition>2nd ed.</edition><publisher-name>U.S. Department of Health and Human Services</publisher-name>;
<year>2018</year>.</mixed-citation>
              </ref>
              <ref id="bibr14-15347354211063500">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winters-Stone</surname><given-names>KM</given-names></name><name><surname>Dobek</surname><given-names>JC</given-names></name><name><surname>Bennett</surname><given-names>JA</given-names></name><name><surname>Maddalozzo</surname><given-names>GF</given-names></name><name><surname>Ryan</surname><given-names>CW</given-names></name><name><surname>Beer</surname><given-names>TM.</given-names></name></person-group><article-title>Skeletal response to resistance and impact training in prostate
cancer survivors</article-title>. <source>Med Sci Sports Exerc</source>.
<year>2014</year>;<volume>46</volume>:<fpage>1482</fpage>-<lpage>1488</lpage>.<pub-id pub-id-type="pmid">24500540</pub-id></mixed-citation>
              </ref>
              <ref id="bibr15-15347354211063500">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winters-Stone</surname><given-names>KM</given-names></name><name><surname>Dieckmann</surname><given-names>N</given-names></name><name><surname>Maddalozzo</surname><given-names>GF</given-names></name><name><surname>Bennett</surname><given-names>JA</given-names></name><name><surname>Ryan</surname><given-names>CW</given-names></name><name><surname>Beer</surname><given-names>TM.</given-names></name></person-group><article-title>Resistance exercise reduces body fat and insulin during
androgen-deprivation therapy for prostate cancer</article-title>.
<source>Oncol Nurs Forum</source>.
<year>2015</year>;<volume>42</volume>:<fpage>348</fpage>-<lpage>356</lpage>.<pub-id pub-id-type="pmid">26148314</pub-id></mixed-citation>
              </ref>
              <ref id="bibr16-15347354211063500">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winters-Stone</surname><given-names>KM</given-names></name><name><surname>Dobek</surname><given-names>JC</given-names></name><name><surname>Bennett</surname><given-names>JA</given-names></name></person-group>, <etal>et al</etal>. <article-title>Resistance training reduces
disability in prostate cancer survivors on androgen deprivation therapy:
evidence from a randomized controlled trial</article-title>. <source>Arch
Phys Med Rehabil</source>.
<year>2015</year>;<volume>96</volume>:<fpage>7</fpage>-<lpage>14</lpage>.<pub-id pub-id-type="pmid">25194450</pub-id></mixed-citation>
              </ref>
              <ref id="bibr17-15347354211063500">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richman</surname><given-names>EL</given-names></name><name><surname>Kenfield</surname><given-names>SA</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Paciorek</surname><given-names>A</given-names></name><name><surname>Carroll</surname><given-names>PR</given-names></name><name><surname>Chan</surname><given-names>JM.</given-names></name></person-group><article-title>Physical activity after diagnosis and risk of prostate cancer
progression: data from the cancer of the prostate strategic urologic
research endeavor</article-title>. <source>Cancer Res</source>.
<year>2011</year>;<volume>71</volume>:<fpage>3889</fpage>-<lpage>3895</lpage>.<pub-id pub-id-type="pmid">21610110</pub-id></mixed-citation>
              </ref>
              <ref id="bibr18-15347354211063500">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winters-Stone</surname><given-names>KM</given-names></name><name><surname>Lyons</surname><given-names>KS</given-names></name><name><surname>Dobek</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal>. <article-title>Benefits of partnered
strength training for prostate cancer survivors and spouses: results from a
randomized controlled trial of the exercising together
project</article-title>. <source>J Cancer Surviv</source>.
<year>2016</year>;<volume>10</volume>:<fpage>633</fpage>-<lpage>644</lpage>.<pub-id pub-id-type="pmid">26715587</pub-id></mixed-citation>
              </ref>
              <ref id="bibr19-15347354211063500">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>SI</given-names></name><name><surname>Scherer</surname><given-names>RW</given-names></name><name><surname>Geigle</surname><given-names>PM</given-names></name></person-group>, <etal>et al</etal>. <article-title>Exercise interventions on
health-related quality of life for cancer survivors</article-title>.
<source>Cochrane Database Syst Rev</source>.
<year>2012</year>;<volume>2012</volume>:CD007566.</mixed-citation>
              </ref>
              <ref id="bibr20-15347354211063500">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langlais</surname><given-names>CS</given-names></name><name><surname>Graff</surname><given-names>RE</given-names></name><name><surname>Van Blarigan</surname><given-names>EL</given-names></name></person-group>, <etal>et al</etal>. <article-title>Post-Diagnostic dietary and
lifestyle factors and prostate cancer recurrence, progression, and
mortality</article-title>. <source>Curr Oncol Rep</source>.
<year>2021</year>;<volume>23</volume>:<fpage>37</fpage>.<pub-id pub-id-type="pmid">33689041</pub-id></mixed-citation>
              </ref>
              <ref id="bibr21-15347354211063500">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guy</surname><given-names>DE</given-names></name><name><surname>Vandersluis</surname><given-names>A</given-names></name><name><surname>Klotz</surname><given-names>LH</given-names></name></person-group>, <etal>et al</etal>. <article-title>Total energy expenditure and
vigorous-intensity physical activity are associated with reduced odds of
reclassification among men on active surveillance</article-title>.
<source>Prostate Cancer Prostatic Dis</source>.
<year>2018</year>;<volume>21</volume>:<fpage>187</fpage>-<lpage>195</lpage>.<pub-id pub-id-type="pmid">29242596</pub-id></mixed-citation>
              </ref>
              <ref id="bibr22-15347354211063500">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenfield</surname><given-names>SA</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Giovannucci</surname><given-names>E</given-names></name><name><surname>Chan</surname><given-names>JM.</given-names></name></person-group><article-title>Physical activity and survival after prostate cancer diagnosis in
the health professionals follow-up study</article-title>. <source>J Clin
Oncol</source>.
<year>2011</year>;<volume>29</volume>:<fpage>726</fpage>-<lpage>732</lpage>.<pub-id pub-id-type="pmid">21205749</pub-id></mixed-citation>
              </ref>
              <ref id="bibr23-15347354211063500">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Jacobs</surname><given-names>EJ</given-names></name><name><surname>Gapstur</surname><given-names>SM</given-names></name></person-group>, <etal>et al</etal>. <article-title>Recreational physical
activity in relation to prostate cancer-specific mortality among men with
nonmetastatic prostate cancer</article-title>. <source>Eur Urol</source>.
<year>2017</year>;<volume>72</volume>:<fpage>931</fpage>-<lpage>939</lpage>.<pub-id pub-id-type="pmid">28711382</pub-id></mixed-citation>
              </ref>
              <ref id="bibr24-15347354211063500">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedenreich</surname><given-names>CM</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Neilson</surname><given-names>HK</given-names></name><name><surname>Kopciuk</surname><given-names>KA</given-names></name><name><surname>McGregor</surname><given-names>SE</given-names></name><name><surname>Courneya</surname><given-names>KS.</given-names></name></person-group><article-title>Physical activity and survival after prostate
cancer</article-title>. <source>Eur Urol</source>.
<year>2016</year>;<volume>70</volume>:<fpage>576</fpage>-<lpage>585</lpage>.<pub-id pub-id-type="pmid">26774959</pub-id></mixed-citation>
              </ref>
              <ref id="bibr25-15347354211063500">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonn</surname><given-names>SE</given-names></name><name><surname>Sjölander</surname><given-names>A</given-names></name><name><surname>Lagerros</surname><given-names>YT</given-names></name></person-group>, <etal>et al</etal>. <article-title>Physical activity and
survival among men diagnosed with prostate cancer</article-title>.
<source>Cancer Epidemiol Biomarkers Prev</source>.
<year>2015</year>;<volume>24</volume>:<fpage>57</fpage>-<lpage>64</lpage>.<pub-id pub-id-type="pmid">25527697</pub-id></mixed-citation>
              </ref>
              <ref id="bibr26-15347354211063500">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>JY</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group>, <etal>et al</etal>. <article-title>Vigorous physical activity
is associated with lower risk of metastatic-lethal progression in prostate
cancer and hypomethylation in the CRACR2A gene</article-title>.
<source>Cancer Epidemiol Biomarkers Prev</source>.
<year>2019</year>;<volume>28</volume>:<fpage>258</fpage>-<lpage>264</lpage>.<pub-id pub-id-type="pmid">30464020</pub-id></mixed-citation>
              </ref>
              <ref id="bibr27-15347354211063500">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ottenbacher</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Moser</surname><given-names>RP</given-names></name><name><surname>Phillips</surname><given-names>SM</given-names></name><name><surname>Alfano</surname><given-names>C</given-names></name><name><surname>Perna</surname><given-names>FM.</given-names></name></person-group><article-title>Population estimates of meeting strength training and aerobic
guidelines, by gender and cancer survivorship status: findings from the
Health Information National Trends Survey (HINTS)</article-title>. <source>J
Phys Act Health</source>.
<year>2015</year>;<volume>12</volume>:<fpage>675</fpage>-<lpage>679</lpage>.<pub-id pub-id-type="pmid">24834485</pub-id></mixed-citation>
              </ref>
              <ref id="bibr28-15347354211063500">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Kenfield</surname><given-names>SA</given-names></name><name><surname>Van Blarigan</surname><given-names>EL</given-names></name></person-group>, <etal>et al</etal>. <article-title>Dietary patterns after
prostate cancer diagnosis in relation to disease-specific and total
mortality</article-title>. <source>Cancer Prev Res</source>.
<year>2015</year>;<volume>8</volume>:<fpage>545</fpage>-<lpage>551</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr29-15347354211063500">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Blarigan</surname><given-names>EL</given-names></name><name><surname>Kenfield</surname><given-names>SA</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>. <article-title>Fat intake after prostate
cancer diagnosis and mortality in the physicians’ health
study</article-title>. <source>Cancer Causes Control</source>.
<year>2015</year>;<volume>26</volume>:<fpage>1117</fpage>-<lpage>1126</lpage>.<pub-id pub-id-type="pmid">26047644</pub-id></mixed-citation>
              </ref>
              <ref id="bibr30-15347354211063500">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richman</surname><given-names>EL</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Paciorek</surname><given-names>A</given-names></name><name><surname>Broering</surname><given-names>JM</given-names></name><name><surname>Carroll</surname><given-names>PR</given-names></name><name><surname>Chan</surname><given-names>JM.</given-names></name></person-group><article-title>Intakes of meat, fish, poultry, and eggs and risk of prostate
cancer progression</article-title>. <source>Am J Clin Nutr</source>.
<year>2010</year>;<volume>91</volume>:<fpage>712</fpage>-<lpage>721</lpage>.<pub-id pub-id-type="pmid">20042525</pub-id></mixed-citation>
              </ref>
              <ref id="bibr31-15347354211063500">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richman</surname><given-names>EL</given-names></name><name><surname>Carroll</surname><given-names>PR</given-names></name><name><surname>Chan</surname><given-names>JM.</given-names></name></person-group><article-title>Vegetable and fruit intake after diagnosis and risk of prostate
cancer progression</article-title>. <source>Int J Cancer</source>.
<year>2012</year>;<volume>131</volume>:<fpage>201</fpage>-<lpage>210</lpage>.<pub-id pub-id-type="pmid">21823116</pub-id></mixed-citation>
              </ref>
              <ref id="bibr32-15347354211063500">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peisch</surname><given-names>SF</given-names></name><name><surname>Van Blarigan</surname><given-names>EL</given-names></name><name><surname>Chan</surname><given-names>JM</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Kenfield</surname><given-names>SA.</given-names></name></person-group><article-title>Prostate cancer progression and mortality: a review of diet and
lifestyle factors</article-title>. <source>World J Urol</source>.
<year>2017</year>;<volume>35</volume>:<fpage>867</fpage>-<lpage>874</lpage>.<pub-id pub-id-type="pmid">27518576</pub-id></mixed-citation>
              </ref>
              <ref id="bibr33-15347354211063500">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>JM</given-names></name><name><surname>Holick</surname><given-names>CN</given-names></name><name><surname>Leitzmann</surname><given-names>MF</given-names></name></person-group>, <etal>et al</etal>. <article-title>Diet after diagnosis and the
risk of prostate cancer progression, recurrence, and death (United
States)</article-title>. <source>Cancer Causes Control</source>.
<year>2006</year>;<volume>17</volume>:<fpage>199</fpage>-<lpage>208</lpage>.<pub-id pub-id-type="pmid">16425098</pub-id></mixed-citation>
              </ref>
              <ref id="bibr34-15347354211063500">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersson</surname><given-names>A</given-names></name><name><surname>Kasperzyk</surname><given-names>JL</given-names></name><name><surname>Kenfield</surname><given-names>SA</given-names></name></person-group>, <etal>et al</etal>. <article-title>Milk and dairy consumption
among men with prostate cancer and risk of metastases and prostate cancer
death</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source>.
<year>2012</year>;<volume>21</volume>:<fpage>428</fpage>-<lpage>436</lpage>.<pub-id pub-id-type="pmid">22315365</pub-id></mixed-citation>
              </ref>
              <ref id="bibr35-15347354211063500">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richman</surname><given-names>EL</given-names></name><name><surname>Kenfield</surname><given-names>SA</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Giovannucci</surname><given-names>EL</given-names></name><name><surname>Chan</surname><given-names>JM.</given-names></name></person-group><article-title>Egg, red meat, and poultry intake and risk of lethal prostate
cancer in the prostate-specific antigen-era: incidence and
survival</article-title>. <source>Cancer Prev Res</source>.
<year>2011</year>;<volume>4</volume>:<fpage>2110</fpage>-<lpage>2121</lpage>.</mixed-citation>
              </ref>
              <ref id="bibr36-15347354211063500">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chavarro</surname><given-names>JE</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Hall</surname><given-names>MN</given-names></name><name><surname>Sesso</surname><given-names>HD</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name></person-group><article-title>A 22-y prospective study of fish intake in relation to prostate
cancer incidence and mortality</article-title>. <source>Am J Clin
Nutr</source>.
<year>2008</year>;<volume>88</volume>:<fpage>1297</fpage>-<lpage>1303</lpage>.<pub-id pub-id-type="pmid">18996866</pub-id></mixed-citation>
              </ref>
              <ref id="bibr37-15347354211063500">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Kenfield</surname><given-names>SA</given-names></name></person-group>, <etal>et al</etal>. <article-title>Nut consumption and prostate
cancer risk and mortality</article-title>. <source>Br J Cancer</source>.
<year>2016</year>;<volume>115</volume>:<fpage>371</fpage>-<lpage>374</lpage>.<pub-id pub-id-type="pmid">27280637</pub-id></mixed-citation>
              </ref>
              <ref id="bibr38-15347354211063500">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vajdi</surname><given-names>M</given-names></name><name><surname>Farhangi</surname><given-names>MA.</given-names></name></person-group><article-title>A systematic review of the association between dietary patterns
and health-related quality of life</article-title>. <source>Health Qual Life
Outcomes</source>.
<year>2020</year>;<volume>18</volume>:<fpage>337</fpage>.<pub-id pub-id-type="pmid">33046091</pub-id></mixed-citation>
              </ref>
              <ref id="bibr39-15347354211063500">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drewnowski</surname><given-names>A</given-names></name><name><surname>Evans</surname><given-names>WJ.</given-names></name></person-group><article-title>Nutrition, physical activity, and quality of life in older
adults: summary</article-title>. <source>J Gerontol A Biol Sci Med
Sci</source>.
<year>2001</year>;<volume>56</volume>:<fpage>89</fpage>-<lpage>94</lpage>.<pub-id pub-id-type="pmid">11730242</pub-id></mixed-citation>
              </ref>
              <ref id="bibr40-15347354211063500">
                <label>40</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morley</surname><given-names>JE.</given-names></name></person-group><article-title>Decreased food intake with aging</article-title>. <source>J
Gerontol A Biol Sci Med Sci</source>.
<year>2001</year>;<volume>56</volume>:<fpage>81</fpage>-<lpage>88</lpage>.<pub-id pub-id-type="pmid">11730241</pub-id></mixed-citation>
              </ref>
              <ref id="bibr41-15347354211063500">
                <label>41</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amarantos</surname><given-names>E</given-names></name><name><surname>Martinez</surname><given-names>A</given-names></name><name><surname>Dwyer</surname><given-names>J.</given-names></name></person-group><article-title>Nutrition and quality of life in older adults</article-title>.
<source>J Gerontol A Biol Sci Med Sci</source>.
<year>2001</year>;<volume>56</volume>:<fpage>54</fpage>-<lpage>64</lpage>.<pub-id pub-id-type="pmid">11730238</pub-id></mixed-citation>
              </ref>
              <ref id="bibr42-15347354211063500">
                <label>42</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bluethmann</surname><given-names>SM</given-names></name><name><surname>Basen-Engquist</surname><given-names>K</given-names></name><name><surname>Vernon</surname><given-names>SW</given-names></name></person-group>, <etal>et al</etal>. <article-title>Grasping the 'teachable
moment': time since diagnosis, symptom burden and health behaviors in
breast, colorectal and prostate cancer survivors</article-title>.
<source>Psychooncology</source>.
<year>2015</year>;<volume>24</volume>:<fpage>1250</fpage>-<lpage>1257</lpage>.<pub-id pub-id-type="pmid">26060053</pub-id></mixed-citation>
              </ref>
              <ref id="bibr43-15347354211063500">
                <label>43</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demark-Wahnefried</surname><given-names>W</given-names></name><name><surname>Aziz</surname><given-names>NM</given-names></name><name><surname>Rowland</surname><given-names>JH</given-names></name><name><surname>Pinto</surname><given-names>BM.</given-names></name></person-group><article-title>Riding the crest of the teachable moment: promoting long-term
health after the diagnosis of cancer</article-title>. <source>J Clin
Oncol</source>.
<year>2005</year>;<volume>23</volume>:<fpage>5814</fpage>-<lpage>5830</lpage>.<pub-id pub-id-type="pmid">16043830</pub-id></mixed-citation>
              </ref>
              <ref id="bibr44-15347354211063500">
                <label>44</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McBride</surname><given-names>CM</given-names></name><name><surname>Clipp</surname><given-names>E</given-names></name><name><surname>Peterson</surname><given-names>BL</given-names></name><name><surname>Lipkus</surname><given-names>IM</given-names></name><name><surname>Demark-Wahnefried</surname><given-names>W.</given-names></name></person-group><article-title>Psychological impact of diagnosis and risk reduction among cancer
survivors</article-title>. <source>Psychooncology</source>.
<year>2000</year>;<volume>9</volume>:<fpage>418</fpage>-<lpage>427</lpage>.<pub-id pub-id-type="pmid">11038480</pub-id></mixed-citation>
              </ref>
              <ref id="bibr45-15347354211063500">
                <label>45</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demark-Wahnefried</surname><given-names>W</given-names></name><name><surname>Peterson</surname><given-names>B</given-names></name><name><surname>McBride</surname><given-names>C</given-names></name><name><surname>Lipkus</surname><given-names>I</given-names></name><name><surname>Clipp</surname><given-names>E.</given-names></name></person-group><article-title>Current health behaviors and readiness to pursue life-style
changes among men and women diagnosed with early stage prostate and breast
carcinomas</article-title>. <source>Cancer</source>.
<year>2000</year>;<volume>88</volume>:<fpage>674</fpage>-<lpage>684</lpage>.<pub-id pub-id-type="pmid">10649263</pub-id></mixed-citation>
              </ref>
              <ref id="bibr46-15347354211063500">
                <label>46</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winters-Stone</surname><given-names>KM</given-names></name><name><surname>Kenfield</surname><given-names>SA</given-names></name><name><surname>Van Blarigan</surname><given-names>EL</given-names></name></person-group>, <etal>et al</etal>. <article-title>Effect of increasing levels
of web-based behavioral support on changes in physical activity, diet, and
symptoms in men with prostate cancer: protocol for a randomized controlled
trial</article-title>. <source>JMIR Res Protoc</source>.
<year>2018</year>;<volume>7</volume>:e11257.</mixed-citation>
              </ref>
              <ref id="bibr47-15347354211063500">
                <label>47</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>JM</given-names></name><name><surname>Van Blarigan</surname><given-names>EL</given-names></name><name><surname>Langlais</surname><given-names>CS</given-names></name></person-group>, <etal>et al</etal>. <article-title>Feasibility and
acceptability of a remotely delivered, web-based behavioral intervention for
men with prostate cancer: four-arm randomized controlled pilot
trial</article-title>. <source>J Med Internet Res</source>.
<year>2020</year>;<volume>22</volume>:e19238.</mixed-citation>
              </ref>
              <ref id="bibr48-15347354211063500">
                <label>48</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lubeck</surname><given-names>DP</given-names></name><name><surname>Litwin</surname><given-names>MS</given-names></name><name><surname>Henning</surname><given-names>JM</given-names></name></person-group>, <etal>et al</etal>. <article-title>The CaPSURE database: a
methodology for clinical practice and research in prostate cancer. CaPSURE
research panel. Cancer of the prostate strategic urologic research
endeavor</article-title>. <source>Urology</source>.
<year>1996</year>;<volume>48</volume>:<fpage>773</fpage>-<lpage>777</lpage>.<pub-id pub-id-type="pmid">8911524</pub-id></mixed-citation>
              </ref>
              <ref id="bibr49-15347354211063500">
                <label>49</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aaronson</surname><given-names>NK</given-names></name><name><surname>Ahmedzai</surname><given-names>S</given-names></name><name><surname>Bergman</surname><given-names>B</given-names></name></person-group>, <etal>et al</etal>. <article-title>The European Organization
for Research and Treatment of cancer QLQ-C30: a quality-of-life instrument
for use in international clinical trials in oncology</article-title>.
<source>J Natl Cancer Inst</source>.
<year>1993</year>;<volume>85</volume>:<fpage>365</fpage>-<lpage>376</lpage>.<pub-id pub-id-type="pmid">8433390</pub-id></mixed-citation>
              </ref>
              <ref id="bibr50-15347354211063500">
                <label>50</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fayers</surname><given-names>PM</given-names></name><name><surname>Aaronson</surname><given-names>NK</given-names></name><name><surname>Bjordal</surname><given-names>K</given-names></name><name><surname>Groenvold</surname><given-names>M</given-names></name><name><surname>Curran</surname><given-names>D</given-names></name><name><surname>Bottomley</surname><given-names>A</given-names></name></person-group>; <collab>EORTC Qulaity of Life Group</collab>. <source>The EORTC
QLQ-C30 Scoring Manual</source>. <edition>3rd ed.</edition><publisher-name>European Organisation for Research and Treatment of
Cancer</publisher-name>; <year>2001</year>.</mixed-citation>
              </ref>
              <ref id="bibr51-15347354211063500">
                <label>51</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cocks</surname><given-names>K</given-names></name><name><surname>King</surname><given-names>MT</given-names></name><name><surname>Velikova</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal>. <article-title>Evidence-based guidelines
for interpreting change scores for the European Organisation for the
Research and Treatment of cancer quality of life questionnaire core
30</article-title>. <source>Eur J Cancer</source>.
<year>2012</year>;<volume>48</volume>:<fpage>1713</fpage>-<lpage>1721</lpage>.<pub-id pub-id-type="pmid">22418017</pub-id></mixed-citation>
              </ref>
              <ref id="bibr52-15347354211063500">
                <label>52</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osoba</surname><given-names>D</given-names></name><name><surname>Rodrigues</surname><given-names>G</given-names></name><name><surname>Myles</surname><given-names>J</given-names></name><name><surname>Zee</surname><given-names>B</given-names></name><name><surname>Pater</surname><given-names>J.</given-names></name></person-group><article-title>Interpreting the significance of changes in health-related
quality-of-life scores</article-title>. <source>J Clin Oncol</source>.
<year>1998</year>;<volume>16</volume>:<fpage>139</fpage>-<lpage>144</lpage>.<pub-id pub-id-type="pmid">9440735</pub-id></mixed-citation>
              </ref>
              <ref id="bibr53-15347354211063500">
                <label>53</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>SF</given-names></name><name><surname>Cella</surname><given-names>D</given-names></name><name><surname>Clauser</surname><given-names>SB</given-names></name></person-group>, <etal>et al</etal>. <article-title>Standardizing
patient-reported outcomes assessment in cancer clinical trials: a
patient-reported outcomes measurement information system
initiative</article-title>. <source>J Clin Oncol</source>.
<year>2007</year>;<volume>25</volume>:<fpage>5106</fpage>-<lpage>5112</lpage>.<pub-id pub-id-type="pmid">17991929</pub-id></mixed-citation>
              </ref>
              <ref id="bibr54-15347354211063500">
                <label>54</label>
                <mixed-citation publication-type="webpage"><collab>System P-ROMI</collab>. <article-title>Patient-reported outcomes
measurement information system. Fatigue: a brief guide to the PROMIS fatigue
instruments</article-title>. <year>2019</year>. Accessed September 3, 2020.
<ext-link xlink:href="http://www.healthmeasures.net/images/PROMIS/manuals/PROMIS_Fatigue_Scoring_Manual.pdf" ext-link-type="uri">http://www.healthmeasures.net/images/PROMIS/manuals/PROMIS_Fatigue_Scoring_Manual.pdf</ext-link></mixed-citation>
              </ref>
              <ref id="bibr55-15347354211063500">
                <label>55</label>
                <mixed-citation publication-type="webpage"><collab>HealthMeasures</collab>. <article-title>Meaningful change for
PROMIS</article-title>. 2020. <comment>Accessed September 3, 2020</comment>.
<ext-link xlink:href="https://www.healthmeasures.net/score-and-interpret/interpret-scores/promis/meaningful-change" ext-link-type="uri">https://www.healthmeasures.net/score-and-interpret/interpret-scores/promis/meaningful-change</ext-link></mixed-citation>
              </ref>
              <ref id="bibr56-15347354211063500">
                <label>56</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buysse</surname><given-names>DJ</given-names></name><name><surname>Reynolds</surname><given-names>CF</given-names></name><name><surname>Monk</surname><given-names>TH</given-names></name><name><surname>Berman</surname><given-names>SR</given-names></name><name><surname>Kupfer</surname><given-names>DJ.</given-names></name></person-group><article-title>The Pittsburgh sleep quality index: a new instrument for
psychiatric practice and research</article-title>. <source>Psychiatry
Res</source>.
<year>1989</year>;<volume>28</volume>:<fpage>193</fpage>-<lpage>213</lpage>.<pub-id pub-id-type="pmid">2748771</pub-id></mixed-citation>
              </ref>
              <ref id="bibr57-15347354211063500">
                <label>57</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mollayeva</surname><given-names>T</given-names></name><name><surname>Thurairajah</surname><given-names>P</given-names></name><name><surname>Burton</surname><given-names>K</given-names></name><name><surname>Mollayeva</surname><given-names>S</given-names></name><name><surname>Shapiro</surname><given-names>CM</given-names></name><name><surname>Colantonio</surname><given-names>A.</given-names></name></person-group><article-title>The Pittsburgh sleep quality index as a screening tool for sleep
dysfunction in clinical and non-clinical samples: a systematic review and
meta-analysis</article-title>. <source>Sleep Med Rev</source>.
<year>2016</year>;<volume>25</volume>:<fpage>52</fpage>-<lpage>73</lpage>.<pub-id pub-id-type="pmid">26163057</pub-id></mixed-citation>
              </ref>
              <ref id="bibr58-15347354211063500">
                <label>58</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eldridge</surname><given-names>SM</given-names></name><name><surname>Chan</surname><given-names>CL</given-names></name><name><surname>Campbell</surname><given-names>MJ</given-names></name></person-group>, <etal>et al</etal>. <article-title>CONSORT 2010 statement:
extension to randomised pilot and feasibility trials</article-title>.
<source>BMJ</source>.
<year>2016</year>;<volume>355</volume>:i5239.</mixed-citation>
              </ref>
              <ref id="bibr59-15347354211063500">
                <label>59</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamaya</surname><given-names>T</given-names></name><name><surname>Hatakeyama</surname><given-names>S</given-names></name><name><surname>Momota</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>. <article-title>Association between the
baseline frailty and quality of life in patients with prostate cancer
(FRAQ-PC study)</article-title>. <source>Int J Clin Oncol</source>.
<year>2021</year>;<volume>26</volume>:<fpage>199</fpage>-<lpage>206</lpage>.<pub-id pub-id-type="pmid">33079283</pub-id></mixed-citation>
              </ref>
              <ref id="bibr60-15347354211063500">
                <label>60</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boeve</surname><given-names>L</given-names></name><name><surname>Hulshof</surname><given-names>M</given-names></name><name><surname>Verhagen</surname><given-names>P</given-names></name></person-group>, <etal>et al</etal>. <article-title>Patient-reported quality of
life in patients with primary metastatic prostate cancer treated with
Androgen deprivation therapy with and without concurrent radiation therapy
to the prostate in a prospective randomised clinical trial; data from the
HORRAD trial</article-title>. <source>Eur Urol</source>.
<year>2021</year>;<volume>79</volume>:<fpage>188</fpage>-<lpage>197</lpage>.<pub-id pub-id-type="pmid">32978014</pub-id></mixed-citation>
              </ref>
              <ref id="bibr61-15347354211063500">
                <label>61</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lardas</surname><given-names>M</given-names></name><name><surname>Liew</surname><given-names>M</given-names></name><name><surname>van den Bergh</surname><given-names>RC</given-names></name></person-group>, <etal>et al</etal>. <article-title>Quality of life outcomes
after primary treatment for clinically localised prostate cancer: a
systematic review</article-title>. <source>Eur Urol</source>.
<year>2017</year>;<volume>72</volume>:<fpage>869</fpage>-<lpage>885</lpage>.<pub-id pub-id-type="pmid">28757301</pub-id></mixed-citation>
              </ref>
              <ref id="bibr62-15347354211063500">
                <label>62</label>
                <mixed-citation publication-type="webpage"><collab>EORTC</collab>. <article-title>Quality of life MID</article-title>.
2020. <comment>Accessed January 20, 2021</comment>. <ext-link xlink:href="https://qol.eortc.org/projectqol/mid/" ext-link-type="uri">https://qol.eortc.org/projectqol/mid/</ext-link></mixed-citation>
              </ref>
              <ref id="bibr63-15347354211063500">
                <label>63</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cocks</surname><given-names>K</given-names></name><name><surname>King</surname><given-names>MT</given-names></name><name><surname>Velikova</surname><given-names>G</given-names></name><name><surname>Martyn St-James</surname><given-names>M</given-names></name><name><surname>Fayers</surname><given-names>PM</given-names></name><name><surname>Brown</surname><given-names>JM.</given-names></name></person-group><article-title>Evidence-based guidelines for determination of sample size and
interpretation of the European Organisation for the Research and Treatment
of Cancer Quality of Life Questionnaire Core 30</article-title>. <source>J
Clin Oncol</source>.
<year>2011</year>;<volume>29</volume>:<fpage>89</fpage>-<lpage>96</lpage>.<pub-id pub-id-type="pmid">21098316</pub-id></mixed-citation>
              </ref>
              <ref id="bibr64-15347354211063500">
                <label>64</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>MT.</given-names></name></person-group><article-title>The interpretation of scores from the EORTC quality of life
questionnaire QLQ-C30</article-title>. <source>Qual Life Res</source>.
<year>1996</year>;<volume>5</volume>:<fpage>555</fpage>-<lpage>567</lpage>.<pub-id pub-id-type="pmid">8993101</pub-id></mixed-citation>
              </ref>
              <ref id="bibr65-15347354211063500">
                <label>65</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musoro</surname><given-names>JZ</given-names></name><name><surname>Bottomley</surname><given-names>A</given-names></name><name><surname>Coens</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>. <article-title>Interpreting European
Organisation for Research and Treatment for Cancer Quality of life
Questionnaire core 30 scores as minimally importantly different for patients
with malignant melanoma</article-title>. <source>Eur J Cancer</source>.
<year>2018</year>;<volume>104</volume>:<fpage>169</fpage>-<lpage>181</lpage>.<pub-id pub-id-type="pmid">30359910</pub-id></mixed-citation>
              </ref>
              <ref id="bibr66-15347354211063500">
                <label>66</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yost</surname><given-names>KJ</given-names></name><name><surname>Eton</surname><given-names>DT</given-names></name><name><surname>Garcia</surname><given-names>SF</given-names></name><name><surname>Cella</surname><given-names>D.</given-names></name></person-group><article-title>Minimally important differences were estimated for six
patient-reported outcomes measurement information system-cancer scales in
advanced-stage cancer patients</article-title>. <source>J Clin
Epidemiol</source>.
<year>2011</year>;<volume>64</volume>:<fpage>507</fpage>-<lpage>516</lpage>.<pub-id pub-id-type="pmid">21447427</pub-id></mixed-citation>
              </ref>
              <ref id="bibr67-15347354211063500">
                <label>67</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuniga</surname><given-names>KB</given-names></name><name><surname>Borno</surname><given-names>H</given-names></name><name><surname>Chan</surname><given-names>JM</given-names></name></person-group>, <etal>et al</etal>. <article-title>The problem of
underrepresentation: black participants in lifestyle trials among patients
with prostate cancer</article-title>. <source>J Racial Ethn Health
Disparities</source>.
<year>2020</year>;<volume>7</volume>:<fpage>996</fpage>-<lpage>1002</lpage>.<pub-id pub-id-type="pmid">32078741</pub-id></mixed-citation>
              </ref>
              <ref id="bibr68-15347354211063500">
                <label>68</label>
                <mixed-citation publication-type="book"><collab>American Cancer Society</collab>. <source>Cancer Facts &amp; Figures for
African Americans 2019-2021</source>. <publisher-name>American Cancer
Society</publisher-name>; <year>2019</year>.</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
